Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 418-000-8 | CAS number: 163062-28-0 BLEU REN 20
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
NOAEL was determined to be 1000 mg/kg/bw.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant guideline study, available as unpublished report, no restrictions, fully adequate for assessment
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River ltalia S.p.A. Calco, Como, Italy.
- Age at study initiation: 27-29g
- Weight at study initiation: 10g
- Housing: Animals were housed five of one sex to in clear polycarbonate cages measuring 59x38.5x20cm with a stainless steel mesh lid and floor (Type 4 Code 1354G Techniplast Gazzada S.a.r.l., Buguggiate, Varese). Each cage tray held absorbent paper which was inspected and changed at least three times a week.
- Diet (e.g. ad libitum): via water bottles, ad libitum
- Water (e.g. ad libitum): commercially available laboratory rodent diet (Altromin MT pelleted diet, A. Rieper, Bolzano, Italy), ad libitum
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2
- Humidity (%): 55±10
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5%
- Details on oral exposure:
- 1000 mg/kg body weight (10 mL/kg bw)
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily
- Remarks:
- Doses / Concentrations:
50, 200, 1000 mg/kg/day
Basis:
actual ingested - No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected in consultation with the sponsor
- Post-exposure recovery period in satellite groups: The control and high dose group also included 5 additional animals per sex sacrified after a 2 week recovery period. - Observations and examinations performed and frequency:
- Clinical signs: All clinical signs were recorded for individual animals. Examination of individual animals for signs of reaction to treatment was carried out daily approx. 24 hours after dosing. Once per treatment week each animal was subjected to an additional physical examination and aany abnormality or sign of ill health was recorded.
Mortality: All animals were checked early in each working day and again in the afternoon to look for dead or moribund animal. At weekends and public holidays the second check was carried out at approx. mid-day.
Body weight: Animals were weighed at the day of allocation, on the day treatment commenced, weekly thereafter and just prior to necropsy.
Food consumption: The weight of food consumed by each cage of rats was recorded at weekly intervals following allocation and the mean daily intake per rat was calculated.
Ophthalmoscopy: Both eyes of all animals initially assigned to the study were examined just prior to the commencement of treatment by means of an opthalmoscope and by a slit-lamp biomicroscope after the instillation of 0.5% tropicamide (Visumidriatic, Merck, Sharpe, and Dohme, Rome, Italy). The eyes of all surviving animals in all groups were re-examined during week 4 of treatment and week 2 of the recovery period.
Clinical pathology investigations: once during week 4 of treatment and once during week 2 of the recovery period samples of blood were withdrawn under light ether anaesthesia from the retro-orbital sinus of all males and females from each group under conditions of food and water deprivation. At the same time interval, individual urine samples were collected from the same animals under the same conditions.
Haematology: Parameters being measured: Hematocrit, Hemoglobin, Red blood cell count, Mean corpuscular hemoglobin, Mean red blood cell volume, Mean corpuscular hemoglobin concentration, white blood cell count, platelets, Differential leucocyte count (neutrophils, lymphocytes, eosinephils, basophils, monocytes), abnormalities of the blood film.
Clinical chemistry: Parameters being measured: alkaline phosphatase, alanine transferase, aspartate transferase, gamma glutamyltransferase, urea, creatinine, glucose, triglycerides, total billirubin, total cholesterol, total protein, sodium, potassium, calcium, chloride, albumin, globulin, phosphorus.
Urinalysis: Parameters being measured: appearance, volume, specific gravity, pH, protein, glucose, ketones, blood, sediment was examined for epithelial cells, polymorphonuclear leucocytes, erythrocytes, crystals, spermatozoa and precursors, other abnormal components. - Sacrifice and pathology:
- Gross pathology: The following organs were dissected free of fat and weighed: adrenal glands, brain, heart, kidneys, liver, ovaries, pituitary gland, spleen, testes, thyroid and parathyroid glands, uterus. The ratios of organ weight to body weight and organ weight to brain weight were calculated.
Histopathology: the following tissues were preserved in 10% buffered formol-saline and processed: abnormalities, adrenal glands, heart, kidneys, liver, spleen and testes. - Statistics:
- For continuous variables the significance of the differences amongst group means were assessed by analysis of variance. Differences between each treated group and the control group were assessed by Dunnett's Test using a pooled error variance. The homogeneity of the data was verified by Barlett's Test before Dunnett's test. If data were found to be inhomogenous a modified T-test (Cochran and Cox) was applied.
- Details on results:
- Mortality: No deaths occurred.
Clinical signs: There were no clinical signs of toxicological importance. Blue feces, observed in the litter tray of treated animals and recorded as cage
data, were considered to be due to the dark blue color of the test substance. For this reason, blue coloration of the skin/fur seen in treated animals, was not recorded as a clinical sign.
Body weight: There were no treatment related differences in body weights. Treated males of the 1000 mg/kg bw group showed a slight reduction in body weight towards the end of treatment when compared with controls. This was not apparent in females.
Food consumption: Not affected by treatment.
Ophthalmoscopy: No significant lesions were observed.
Hematology: Values in treated animals remained generally comparable to controls. The statistically significant variations observed were either confined to the low dose and intermediate groups and/or fell within the normal range of archive data.
Clinical chemistry: The statistically significant differences between control and treated groups were often inconsistent between groups and sexes. Both males and females in the high dose group (1000 mg/kg/day), showed statistically significant reductions in total protein and increases in chloride and inorganic phosphorus. However, those values fell within the normal range of archive data. The changes were not apparent at the end of the recovery period. The plasma of most treated animals showed a pale green to blue coloration, the intensity of which was related to the dose level of the test substance administered. Some coloration was also apparent in the plasma of three of the high dose recovery animals, but to a much lesser degree.
Urinalysis: The values for urinalysis were generally comparable to those of controls. The urine of all animals in the high dose group (1000 mg/kg/day) showed a blue/green coloration which, after approximately two weeks of recovery became light green.
Organ weights: Thyroid weights were statistically significantly lower than study control values in all treated groups and recovery females of the high dose group (1000 mg/kg/day). All these values were within the range of historical control data and no dose response relationship was evident, Furthermore, no evidence of histological change was seen in this organ. This appears to indicate that this change may be spontaneous in nature and not related to treatment.
Macroscopic observations: Blue staining was observed in several organs and tissues, particularly in animals of the high dose group (1000 mg/kg/day). This coloration, considered to be due to the blue color of the test substance, was still evident in recovery animals of this group.
Microscopic observations: Blue pigmentation, considered to be due to the test substance and/or it's metabolites, was observed in the cortical tubular cells of the kidneys and the interstitium of the testes of both test (receiving 1000 mg/kg/day) and recovery animals. Renal tubular cell vacuolation was noted in the female showing the highest degree of severity of blue pigmentation. The toxicological significance of this finding is not known in detail but is considered to be a sign of substance absorption, distribution and excretion. The remaining changes observed were considered to be an expression of spontaneous pathology. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: clinical signs; mortality; body weight; food consumption; ophthalmoscopic examination; haematology; clinical chemistry; urinalysis; organ weights; macroscopic and microscopic observations
- Critical effects observed:
- not specified
- Conclusions:
- NOAEL was determined to be 1000 mg/kg/bw.
- Executive summary:
In a GLP compliant repeated toxicity study, performed according to OECD guideline 407, CD rats of Sprague Dawley origin were treated with the test substance (50, 200, and 1000 mg/kg bw) by repeated oral gavage, for a period of 28 days. The study was comprised of four groups, each containing five male and five female rats. For the post-exposure recovery period two satellite groups exposed to 0 and 1000 mg/kg bw for 28 days consisting of five male and five female rats each were monitored for an additional 14 days after the end of the 28 days treatment period. No treatment related effects were observed on mortality, clinical signs, body weight, food consumption, ophthalmic examinations, clinical pathology investigations, and organ weight. An abnormal blue color was observed at the macroscopic examination in several organs and tissues mainly of animals receiving 1000 mg/kg/day. Blue pigmentation was observed microscopically in the kidneys and testes of treated animals receiving 1000 mg/kg/day, sacrificed after 4 weeks of treatment. This finding was still evident after two week of recovery. The toxicological significance of this finding is not known in detail, but is considered to be a sign of test substance absorption, distribution and excretion. This data indicates that the test substance is well tolerated at all dose levels, suggesting a NOAEL of 1000 mg/kg bw.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- GLP compliant guideline study, klimisch 1
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a GLP compliant repeated toxicity study, performed according to OECD guideline 407, CD rats of Sprague Dawley origin were treated with the test substance (50, 200, and 1000 mg/kg bw) by repeated oral gavage, for a period of 28 days (RTC 1995). The study was comprised of four groups, each containing five male and five female rats. For the post-exposure recovery period two satellite groups exposed to 0 and 1000 mg/kg bw for 28 days consisting of five male and five female rats each were monitored for an additional 14 days after the end of the 28 days treatment period. No treatment related effects were observed on mortality, clinical signs, body weight, food consumption, ophthalmic examinations, clinical pathology investigations, and organ weight. An abnormal blue color was observed at the macroscopic examination in several organs and tissues mainly of animals receiving 1000 mg/kg/day. Blue pigmentation was observed microscopically in the kidneys and testes of treated animals receiving 1000 mg/kg/day, sacrificed after 4 weeks of treatment. This finding was still evident after two week of recovery. The toxicological significance of this finding is not known in detail, but is considered to be a sign of test substance absorption, distribution and excretion. This data indicates that the test substance is well tolerated at all dose levels, suggesting a NOAEL of 1000 mg/kg bw.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Only study available
Justification for classification or non-classification
Based on the findings of the repeated dose toxicity study, the test substance does meet the criteria of the Directive 67/548/EEC and the EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.